NYSE:TMO

Thermo Fisher Scientific Competitors

$484.21
+3.80 (+0.79 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$478.89
Now: $484.21
$488.83
50-Day Range
$439.85
MA: $460.68
$494.38
52-Week Range
$319.87
Now: $484.21
$532.57
Volume1.08 million shs
Average Volume1.80 million shs
Market Capitalization$190.30 billion
P/E Ratio39.69
Dividend Yield0.22%
Beta0.85

Competitors

Thermo Fisher Scientific (NYSE:TMO) Vs. ILMN, A, MTD, BIO, WAT, and CRL

Should you be buying TMO stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Thermo Fisher Scientific, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), and Charles River Laboratories International (CRL).

Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Illumina and Thermo Fisher Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion16.83$1.00 billion$6.5762.16
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Illumina and Thermo Fisher Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina48602.11
Thermo Fisher Scientific021802.90

Illumina presently has a consensus target price of $370.5789, suggesting a potential downside of 9.27%. Thermo Fisher Scientific has a consensus target price of $536.8947, suggesting a potential upside of 10.88%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Profitability

This table compares Illumina and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
Thermo Fisher Scientific17.12%21.35%10.55%

Risk & Volatility

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Institutional & Insider Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.4% of Illumina shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Thermo Fisher Scientific beats Illumina on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Agilent Technologies and Thermo Fisher Scientific's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.68$719 million$3.2841.02
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21

Thermo Fisher Scientific has higher revenue and earnings than Agilent Technologies. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Agilent Technologies and Thermo Fisher Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies071902.73
Thermo Fisher Scientific021802.90

Agilent Technologies presently has a consensus target price of $106.1850, suggesting a potential downside of 21.07%. Thermo Fisher Scientific has a consensus target price of $536.8947, suggesting a potential upside of 10.88%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Agilent Technologies.

Dividends

Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 1 consecutive years and Thermo Fisher Scientific has raised its dividend for 3 consecutive years.

Profitability

This table compares Agilent Technologies and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
Thermo Fisher Scientific17.12%21.35%10.55%

Risk & Volatility

Agilent Technologies has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Thermo Fisher Scientific beats Agilent Technologies on 11 of the 17 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Mettler-Toledo International and Thermo Fisher Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion10.09$561.11 million$22.7757.16
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21

Thermo Fisher Scientific has higher revenue and earnings than Mettler-Toledo International. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Mettler-Toledo International has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Mettler-Toledo International and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Thermo Fisher Scientific17.12%21.35%10.55%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mettler-Toledo International and Thermo Fisher Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International25101.88
Thermo Fisher Scientific021802.90

Mettler-Toledo International presently has a consensus target price of $971.3750, suggesting a potential downside of 25.37%. Thermo Fisher Scientific has a consensus target price of $536.8947, suggesting a potential upside of 10.88%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats Thermo Fisher Scientific on 9 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

63.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 27.5% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Thermo Fisher Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion8.26$1.76 billion$7.0690.61
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Bio-Rad Laboratories and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Thermo Fisher Scientific17.12%21.35%10.55%

Analyst Recommendations

This is a summary of recent ratings and price targets for Bio-Rad Laboratories and Thermo Fisher Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Thermo Fisher Scientific021802.90

Bio-Rad Laboratories currently has a consensus target price of $700.00, suggesting a potential upside of 9.42%. Thermo Fisher Scientific has a consensus target price of $536.8947, suggesting a potential upside of 10.88%. Given Thermo Fisher Scientific's higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 10 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

91.8% of Waters shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 1.5% of Waters shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Waters and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
Thermo Fisher Scientific17.12%21.35%10.55%

Analyst Recommendations

This is a summary of recent ratings and price targets for Waters and Thermo Fisher Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters48101.77
Thermo Fisher Scientific021802.90

Waters currently has a consensus target price of $224.20, suggesting a potential downside of 26.40%. Thermo Fisher Scientific has a consensus target price of $536.8947, suggesting a potential upside of 10.88%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Waters.

Volatility & Risk

Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Valuation & Earnings

This table compares Waters and Thermo Fisher Scientific's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.86$592.20 million$8.9933.89
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21

Thermo Fisher Scientific has higher revenue and earnings than Waters. Waters is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Waters on 8 of the 14 factors compared between the two stocks.

Thermo Fisher Scientific (NYSE:TMO) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Charles River Laboratories International10.68%22.41%7.66%

Analyst Recommendations

This is a summary of recent recommendations for Thermo Fisher Scientific and Charles River Laboratories International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific021802.90
Charles River Laboratories International031102.79

Thermo Fisher Scientific currently has a consensus price target of $536.8947, suggesting a potential upside of 10.88%. Charles River Laboratories International has a consensus price target of $254.7143, suggesting a potential downside of 22.27%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Charles River Laboratories International.

Risk & Volatility

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Earnings & Valuation

This table compares Thermo Fisher Scientific and Charles River Laboratories International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.45$3.70 billion$12.3539.21
Charles River Laboratories International$2.62 billion6.28$252.02 million$6.7348.69

Thermo Fisher Scientific has higher revenue and earnings than Charles River Laboratories International. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Charles River Laboratories International on 9 of the 14 factors compared between the two stocks.


Thermo Fisher Scientific Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.6$408.42+1.2%$59.62 billion$3.54 billion94.76Upcoming Earnings
Insider Selling
Agilent Technologies logo
A
Agilent Technologies
1.8$134.53+0.5%$40.99 billion$5.34 billion58.49
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,301.56+0.7%$30.35 billion$3.01 billion54.76News Coverage
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.3$639.73+0.8%$19.09 billion$2.31 billion5.48Upcoming Earnings
News Coverage
Waters logo
WAT
Waters
1.3$304.64+1.1%$18.91 billion$2.41 billion37.94
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$327.70+1.1%$16.45 billion$2.62 billion54.62Analyst Downgrade
Bio-Techne logo
TECH
Bio-Techne
2.0$423.71+0.0%$16.44 billion$738.69 million67.79
PerkinElmer logo
PKI
PerkinElmer
1.9$133.39+0.4%$14.95 billion$2.88 billion36.25
Bruker logo
BRKR
Bruker
1.9$67.44+0.4%$10.22 billion$2.07 billion66.12
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$30.48+0.8%$6.05 billion$90.89 million-108.85Upcoming Earnings
News Coverage
Luminex logo
LMNX
Luminex
1.5$36.71+0.0%$1.74 billion$334.64 million94.13Analyst Report
Fluidigm logo
FLDM
Fluidigm
1.8$4.60+0.4%$344.83 million$117.24 million-6.87
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.51+0.5%$259.93 million$116.18 million-36.17Analyst Downgrade
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.02+5.2%$64.36 million$420,000.00-1.51
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.